E&G Advisors LP trimmed its position in shares of Pfizer (NYSE:PFE) by 34.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,561 shares of the biopharmaceutical company’s stock after selling 19,497 shares during the period. E&G Advisors LP’s holdings in Pfizer were worth $1,324,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in PFE. Vanguard Group Inc. boosted its holdings in shares of Pfizer by 2.3% in the second quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Pfizer by 4.4% in the third quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares during the period. Franklin Resources Inc. boosted its holdings in shares of Pfizer by 0.9% in the second quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Pfizer by 4.8% in the second quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares during the period. Finally, Fisher Asset Management LLC boosted its holdings in shares of Pfizer by 3.2% in the third quarter. Fisher Asset Management LLC now owns 35,120,799 shares of the biopharmaceutical company’s stock valued at $1,253,813,000 after acquiring an additional 1,085,437 shares during the period. Hedge funds and other institutional investors own 71.20% of the company’s stock.
In other news, EVP Sally Susman sold 33,368 shares of the firm’s stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $37.03, for a total value of $1,235,617.04. Following the completion of the transaction, the executive vice president now owns 191,505 shares in the company, valued at $7,091,430.15. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the transaction, the insider now owns 36,959 shares of the company’s stock, valued at approximately $1,374,505.21. The disclosure for this sale can be found here. Insiders sold 248,037 shares of company stock valued at $9,064,785 in the last quarter. 0.06% of the stock is currently owned by company insiders.
Several equities research analysts have recently weighed in on PFE shares. Vetr raised Pfizer from a “hold” rating to a “buy” rating and set a $37.98 price objective for the company in a report on Monday, January 8th. BMO Capital Markets set a $39.00 price objective on Pfizer and gave the company a “buy” rating in a report on Monday, January 8th. Morgan Stanley set a $41.00 price objective on Pfizer and gave the company a “buy” rating in a report on Friday, January 5th. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $41.00 price objective for the company in a report on Wednesday, January 17th. Finally, Sanford C. Bernstein set a $43.00 price objective on Pfizer and gave the company a “buy” rating in a report on Tuesday, January 30th. Two investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have issued a buy rating to the company’s stock. Pfizer currently has an average rating of “Hold” and an average price target of $39.25.
NYSE:PFE traded down $0.56 during trading hours on Friday, hitting $35.17. The company’s stock had a trading volume of 21,065,662 shares, compared to its average volume of 22,138,338. The stock has a market capitalization of $212,695.86, a price-to-earnings ratio of 13.27, a PEG ratio of 1.78 and a beta of 0.90. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.10 and a current ratio of 1.35. Pfizer has a 52-week low of $31.67 and a 52-week high of $39.43.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.56 by $0.06. The firm had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. Pfizer had a return on equity of 25.21% and a net margin of 40.55%. Pfizer’s revenue was up .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.47 earnings per share. analysts predict that Pfizer will post 2.96 EPS for the current year.
Pfizer declared that its Board of Directors has authorized a share repurchase plan on Monday, December 18th that permits the company to repurchase $10.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to reacquire shares of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s leadership believes its stock is undervalued.
TRADEMARK VIOLATION WARNING: This piece was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/04/07/eg-advisors-lp-cuts-stake-in-pfizer-inc-pfe.html.
Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.